Houston hardtech accelerator names 8 scientists to 2025 cohort

ready, set, activate

Activate Houston has named eight fellows to its 2025 cohort. Photo courtesy the Ion.

National hardtech-focused organization Activate has named its 2025 cohort of scientists, which includes new members to Activate Houston.

The Houston hub was introduced last year, and joins others in Boston, New York, and Berkley, California—where Activate is headquartered. The organization also offers a virtual and remote cohort, known as Activate Anywhere. Collectively, the 2025 Activate Fellowship consists of 47 scientists and engineers from nine U.S. states.

This year's cohort comprises subject matter experts across various fields, including quantum, robotics, biology, agriculture, energy and direct air capture.

Activate aims to support scientists at "the outset of their entrepreneurial journey." It partners with U.S.-based funders and research institutions to support its fellows in developing high-impact technology. The fellows receive a living stipend, connections from Activate's robust network of mentors and access to a curriculum specific to the program for two years.

“Science entrepreneurship is the origin story of tomorrow’s industries,” Cyrus Wadia, CEO of Activate, said in an announcement. “The U.S. has long been a world center for science leadership and technological advancement. When it comes to solving the world’s biggest challenges, hard-tech innovation is how we unlock the best solutions. From infrastructure to energy to agriculture, these Activate Fellows are the bold thinkers who are building the next generation of science-focused companies to lead us into the future.”

The Houston fellows selected for the 2025 class include:

  • Jonathan Bessette, founder and CEO of KIRA, which uses its adaptive electrodialysis system to treat diverse water sources and reduce CO2 emissions
  • Victoria Coll Araoz, co-founder and chief science officer of Florida-based SEMION, an agricultural technology company developing pest control strategies by restoring crops' natural defenses
  • Eugene Chung, co-founder and CEO of Lift Biolabs, a biomanufacturing company developing low-cost, nanobubble-based purification reagents. Chung is completing his Ph.D. in bioengineering at Rice University.
  • Isaac Ju, co-founder of EarthFlow AI, which has developed an AI-powered platform for subsurface modeling, enabling the rapid scaling of carbon storage, geothermal energy and lithium extraction
  • Junho Lee, principal geotechnical engineer of Houston-based Deep Anchor Solutions, a startup developing innovative anchoring systems for floating renewables and offshore infrastructure
  • Sotiria (Iria) Mostrou, principal inventor at Houston-based Biosimo Chemicals, a chemical engineering startup that develops and operates processes to produce bio-based platform chemicals
  • Becca Segel, CEO and founder of Pittsburgh-based FlowCellutions, which prevents power outages for critical infrastructure such as hospitals, data centers and the grid through predictive battery diagnostics
  • Joshua Yang, CEO and co‑founder of Cambridge, Massachusetts-based Brightlight Photonics, which develops chip-scale titanium: sapphire lasers to bring cost-effective, lab-grade performance to quantum technologies, diagnostics and advanced manufacturing

The program, led locally by Houston Managing Director Jeremy Pitts, has supported 296 Activate fellows since the organization was founded in 2015. Members have gone on to raise roughly $4 billion in follow-on funding, according to Activate's website.

Activate officially named its Houston office in the Ion last year.

Charlie Childs, co-founder and CEO of Intero Biosystems, which won both the top-place finish and the largest total investment at this year's Rice Business Plan Competition, was named to the Activate Anywhere cohort. Read more about the Boston, New York, Berkley and Activate Anywhere cohorts here.

From Your Site Articles
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

UH researchers make breakthrough in cutting carbon capture costs

carbon breakthrough

A team of researchers at the University of Houston has made two breakthroughs in addressing climate change and potentially reducing the cost of capturing harmful emissions from power plants.

Led by Professor Mim Rahimi at UH’s Cullen College of Engineering, the team released two significant publications that made significant strides relating to carbon capture processes. The first, published in Nature Communications, introduced a membraneless electrochemical process that cuts energy requirements and costs for amine-based carbon dioxide capture during the acid gas sweetening process. Another, featured on the cover of ES&T Engineering, demonstrated a vanadium redox flow system capable of both capturing carbon and storing renewable energy.

“These publications reflect our group’s commitment to fundamental electrochemical innovation and real-world applicability,” Rahimi said in a news release. “From membraneless systems to scalable flow systems, we’re charting pathways to decarbonize hard-to-abate sectors and support the transition to a low-carbon economy.”

According to the researchers, the “A Membraneless Electrochemically Mediated Amine Regeneration for Carbon Capture” research paper marked the beginning of the team’s first focus. The research examined the replacement of costly ion-exchange membranes with gas diffusion electrodes. They found that the membranes were the most expensive part of the system, and they were also a major cause of performance issues and high maintenance costs.

The researchers achieved more than 90 percent CO2 removal (nearly 50 percent more than traditional approaches) by engineering the gas diffusion electrodes. According to PhD student and co-author of the paper Ahmad Hassan, the capture costs approximately $70 per metric ton of CO2, which is competitive with other innovative scrubbing techniques.

“By removing the membrane and the associated hardware, we’ve streamlined the EMAR workflow and dramatically cut energy use,” Hassan said in the news release. “This opens the door to retrofitting existing industrial exhaust systems with a compact, low-cost carbon capture module.”

The second breakthrough, published by PhD student Mohsen Afshari, displayed a reversible flow battery architecture that absorbs CO2 during charging and releases it upon discharge. The results suggested that the technology could potentially provide carbon removal and grid balancing when used with intermittent renewables, such as solar or wind power.

“Integrating carbon capture directly into a redox flow battery lets us tackle two challenges in one device,” Afshari said in the release. “Our front-cover feature highlights its potential to smooth out renewable generation while sequestering CO2.”

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston brain, spine cancer diagnostics company to launch patient testing

fighting cancer

A Houston-based company is beginning a push on its proven test for central nervous system (CNS) cancers.

“We're going to start rolling out just in Texas and doing patient testing in the state of Texas, first with a few accounts where we've established a relationship, and then we'll continue our rollout through the United States in the next year or so,” says Russell Bradley, president and general manager of CNSide Diagnostics.

Bradley had retired from multinational diagnostics company Abbott Laboratories when he met Marc Hendrick, the CEO of Austin’s Plus Therapeutics, last year. When Hendrick told him about the recent acquisition of CNSide, a company formerly based in San Diego, Bradley says he felt compelled to join in its mission.

CNSide’s CSF assay tests cerebrospinal fluid for cancers that have metastasized to the spine or brain, primarily carcinomas and melanomas.

“Typically, they do an MRI, and that won't always show anything. If it's early stage, they do cytology, which is not very sensitive at finding cancer cells in the cerebrospinal fluid. By the time they're diagnosed, it can be very late-stage, and oftentimes, in fact, the studies show that half of these patients don't get treated,” Bradley says.

CNSide, then, is a ray of hope for patients who are often consigned to palliative care. By diagnosing their metastasis sooner, physicians have more treatment options to stop the CNS cancer before it’s wreaked havoc. Bradley also points out that once a treatment regimen is underway, doctors can continue to measure the cancer’s progress or lack thereof. He claims that, of the roughly 300 neuro-oncologists in the United States, about 200 have already used the test.

Moving from California to Houston briefly slowed progress for CNSide, but now, matters are moving ahead at a steady clip.

“It takes a little bit of time to establish the test in a new location, move the apparatus and establish the processes,” Bradley says. “You have to get the lab accredited, which we just did. So we're now accredited to run patient samples, and we've really just been doing our research samples as part of the clinical studies.”

Texas institutions, such as the University of Texas - Southwestern, MD Anderson Cancer Center, Mays Cancer Center, Baylor Scott & White Health and Texas Oncology, are beginning to use the technology.

Bradley, who lives in Austin but spends much of his time in Houston, says that the city has been nothing less than an ideal fit for the needs of his growing company and a lab that’s currently hiring. He praises the logistics potential of being close to a major hub, which will eventually be a key factor for getting lumbar puncture samples from around the country to the lab for quick testing.

“I think the business environment in Texas, generally, and in Houston, specifically, for us and the access to talent with a lot of institutions here around the Houston area that graduate the type of people that we want to employ is remarkable. And I'd say the cherry on top is really just access to world-class institutions like MD Anderson. I think from a holistic and comprehensive point of view, Houston has a lot to offer a company like us,” Bradley says.

And ultimately, what brought Bradley and CNSide to Texas is the quest to prolong the lives of people living with cancer. As he puts it, “It's a true privilege—and I know I speak on behalf of the team at CNSide and Plus—to be able to impact these patients and have the tools at this time in the history of cancer diagnostics to be able to really make a difference.”

Houston autonomous trucking co. completes first test run without human intervention

on the road

Houston-based Bot Auto, an autonomous trucking company, has completed its first test run without human assistance. Bot Auto conducted the test in Houston.

“The truck operated seamlessly within its defined operational domain with no one in the cab or remote assistance, navigating real-world traffic conditions,” the company said in a news release. “The run was executed at sunset, successfully navigating day and night operations.”

Bot Auto, a transportation-as-a-service startup, added that this milestone “serves as a validation benchmark, demonstrating the maturity and safety of Bot Auto’s autonomy stack and test protocols.”

The successful test comes two years after Xiaodi Hou, a globally recognized expert in autonomous vehicles, founded Bot Auto.

“This validation run is a meaningful step, but it’s a waypoint, not the destination,” Hou, CEO of Bot Auto, added in the release. “Success is simple: Autonomy must beat human cost-per-mile, consistently and safely. And at Bot Auto, humanless means no human — not in the driver’s seat, not in the back seat, and not behind a remote joystick.”

For several months, Bot Auto has been conducting autonomous trucking tests on a Houston-to-San Antonio route. In the coming months, Bot Auto will operate its first commercial cargo run without human assistance between its Houston and San Antonio hubs.

“Our mission is to revolutionize the transportation industry with our autonomous trucks, making a lasting positive impact on humanity,” the company says.

Last October, Bot Auto announced it had raised $20 million in pre-series A funding from Brightway Future Capital, Cherubic Ventures, EnvisionX Capital, First Star Ventures, Linear Capital, M31 Capital, Taihill Venture, Uphonest Capital, and Welight Capital.

This summer, Hou told the Front Lines podcast that Bot Auto had raised more than $45 million altogether.
View All Listings